MX2019001919A - Vacunas virales. - Google Patents

Vacunas virales.

Info

Publication number
MX2019001919A
MX2019001919A MX2019001919A MX2019001919A MX2019001919A MX 2019001919 A MX2019001919 A MX 2019001919A MX 2019001919 A MX2019001919 A MX 2019001919A MX 2019001919 A MX2019001919 A MX 2019001919A MX 2019001919 A MX2019001919 A MX 2019001919A
Authority
MX
Mexico
Prior art keywords
chikungunya
zika virus
smallpox infection
virus
viral vaccines
Prior art date
Application number
MX2019001919A
Other languages
English (en)
Inventor
Howley Paul
Original Assignee
Sementis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903295A external-priority patent/AU2016903295A0/en
Application filed by Sementis Ltd filed Critical Sementis Ltd
Publication of MX2019001919A publication Critical patent/MX2019001919A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición para provocar una respuesta inmune en animales que disminuye el riesgo de infección por chikungunya y viruela, virus Zika e infección por viruela, y/o chikungunya, virus Zika e infección por viruela. La composición comprende un portador farmacéuticamente aceptable y un poxvirus atenuado, en donde el genoma del poxvirus comprende una secuencia de ácido nucleico que codifica la poliproteína subgenómica 26S del virus chikungunya y/o la PrME del virus Zika.
MX2019001919A 2016-08-19 2017-08-18 Vacunas virales. MX2019001919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016903295A AU2016903295A0 (en) 2016-08-19 Viral Vaccines
PCT/AU2017/050879 WO2018032057A1 (en) 2016-08-19 2017-08-18 Viral vaccines

Publications (1)

Publication Number Publication Date
MX2019001919A true MX2019001919A (es) 2019-09-04

Family

ID=61195904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001919A MX2019001919A (es) 2016-08-19 2017-08-18 Vacunas virales.

Country Status (17)

Country Link
US (2) US10905759B2 (es)
EP (2) EP3500280A4 (es)
JP (1) JP2019528271A (es)
KR (1) KR20190050787A (es)
CN (1) CN109862909A (es)
AR (1) AR110624A1 (es)
AU (1) AU2017313450B2 (es)
BR (1) BR112019003181A2 (es)
CA (1) CA3034282A1 (es)
CL (1) CL2019000405A1 (es)
IL (1) IL264893B (es)
MA (1) MA45994A (es)
MX (1) MX2019001919A (es)
NZ (1) NZ750578A (es)
SG (1) SG11201900814QA (es)
TW (1) TWI728173B (es)
WO (1) WO2018032057A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3911010B2 (ja) * 1994-04-29 2007-05-09 イムノ・アクテイエンゲゼルシヤフト 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス
CN1418951A (zh) 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
WO2003097846A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
KR20040015624A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
DK1594970T3 (da) * 2003-02-18 2008-11-17 Helmholtz Zentrum Muenchen Fremgangsmåde til generering af rekombinant MVA
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
EP2618840A2 (en) * 2010-09-23 2013-07-31 Baxter International Inc. Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
CN105163756A (zh) * 2013-03-15 2015-12-16 赛门蒂斯有限公司 免疫调节
CN106255758B (zh) * 2013-11-01 2020-06-23 赛门蒂斯有限公司 病毒载体制造
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition
BR112018015696A2 (pt) * 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus

Also Published As

Publication number Publication date
AU2017313450B2 (en) 2024-02-15
BR112019003181A2 (pt) 2019-07-16
TW201809273A (zh) 2018-03-16
IL264893A (es) 2019-04-30
NZ750578A (en) 2023-05-26
TWI728173B (zh) 2021-05-21
WO2018032057A1 (en) 2018-02-22
AU2017313450A1 (en) 2019-02-28
CN109862909A (zh) 2019-06-07
IL264893B (en) 2022-08-01
CL2019000405A1 (es) 2019-06-14
KR20190050787A (ko) 2019-05-13
CA3034282A1 (en) 2018-02-22
EP4331676A3 (en) 2024-05-15
JP2019528271A (ja) 2019-10-10
SG11201900814QA (en) 2019-03-28
EP4331676A2 (en) 2024-03-06
US20210113684A1 (en) 2021-04-22
US10905759B2 (en) 2021-02-02
US20200009245A1 (en) 2020-01-09
RU2019107582A (ru) 2020-09-21
MA45994A (fr) 2021-03-17
AR110624A1 (es) 2019-04-17
EP3500280A4 (en) 2020-05-13
EP3500280A1 (en) 2019-06-26
RU2019107582A3 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
NZ729012A (en) Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
BR112018009032A2 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
WO2016109792A3 (en) Novel multivalent nanoparticle-based vaccines
CO7160021A2 (es) Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
IN2015DN02546A (es)
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
BR112018012642A2 (pt) vacina de calicivírus felino
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
NZ750578A (en) Viral vaccines
PH12018502460A1 (en) Arthrogenic alphavirus vaccine
PH12017501165A1 (en) Dengue virus vaccine compositions and methods of use thereof
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
PH12020551944A1 (en) Reverse peptide vaccine
MX2019007924A (es) Vacunas contra la influenza.
PH12017500419B1 (en) Recoded arbovirus and vaccines
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
EA201790506A1 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)